The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer
Open accessAbstract
Purpose: To determine the antitumor activity of ABX-EGF, a fully human monoclonal antibody to the epidermal growth factor receptor (EGFr), in previously treated patients with metastatic renal cell carcinoma, and to characterize its toxicity, immunogenicity, pharmacokinetics, and pharmacodynamics. Patients and Methods: The antitumor activity, as well as the toxicity, pharmacokinetics, pharmacodynamics, and immunogenicity of ABX-EGF, were assessed. Results: Eighty-eight patients were treated with ABX-EGF doses of 1.0, 1.5, 2.0, or 2.5 mg/kg weekly with no loading dose. EGFr immunostaining was performed on 76 tumor biopsy specimens (86%), and 69 (91%) scored positive. Major responses occurred in three patients, and two patients had minor responses. Forty-four patients (50%) also had stable disease at their first 8-week assessment, and the median progression-free survival (PFS) was 100 days (95% CI, 58 to 140 days). Low hemoglobin and high alkaline phosphatase predicted for short PFS. The principal toxicity, an acneiform rash, occurred in 68%, 95%, 87%, and 100% of patients who received at least three doses of ABX-EGF at 1.0, 1.5, 2.0, and 2.5 mg/kg/wk, respectively. A trend indicated that the severity of the rash may relate to PFS. No human antihuman antibodies were detected. ABX-EGF pharmacokinetics fit a model that incorporated both linear and saturable EGFr-mediated clearance mechanisms, and interindividual variability was low. At 2.5 mg/kg/wk, ABX-EGF concentrations throughout treatment exceeded those estimated to saturate nonlinear clearance and inhibit xenograft growth by 90%. Conclusion: ABX-EGF was generally well tolerated. The objective response rate was low in previously treated patients with metastatic renal cell carcinoma. Although skin rash may be a pharmacodynamic marker of drug action, its potential as a surrogate marker of clinical benefit requires further evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255
Applied pharmacokinetics : principles of therapeutic drug monitoring
Evans, W. E., Schentag, J. J., & Jusko, W. J. (1992) · Medical Entomology and Zoology · Cited by 1,044
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Self-citationCiardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
BindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., White, D. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.122 · Cited by 790
Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 763
Self-citationOber, R. J., Radu, C. G., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 501
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
Yang, X. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00134-7 · Cited by 463
Fan, Z., Baselga, J. M., Masui, H., & Mendelsohn, J. M. (1993) · PubMed · Cited by 456
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.
Mendelsohn, J. M. (1997) · PubMed · Cited by 344
Yang, X., Jia, X., Corvalan, J. R. F., Wang, P., Davis, C., & Jakobovits, A. (1999) · PubMed · Cited by 328
Radinsky, R., Risin, S. A., Fan, D., Dong, Z., Bielenberg, D. R., Bucana, C. D., & Fidler, I. J. (1995) · PubMed · Cited by 321
Ludden, T. M., Beal, S. L., & Sheiner, L. B. (1994) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353864 · Cited by 306
Porębska, I., Harłozińska, A., & Bojarowski, T. (2000) · Tumor Biology · doi:10.1159/000030116 · Cited by 234
Scher, H. I., Sarkis, A. S., Reuter, V., Cohen, D., Netto, G. J., Petrylak, D. P., LIANES, P., FUKS, Z. Y., Mendelsohn, J. M., & Cordon‐Cardo, C. (1995) · PubMed · Cited by 214
Perez-Soler, R. (2001) · Medical Entomology and Zoology · Cited by 189
Transcytosis and Catabolism of Antibody
Ghetie, V. F., & Ward, E. S. (2002) · Immunologic Research · doi:10.1385/ir:25:2:097 · Cited by 163
Motzer, R. J., Amato, R. J., Todd, M. B., Poo, W.-J., Cohen, R. B., Baselga, J. M., Muss, H. B., Cooper, M. R., Yu, R., Ginsberg, M. S., et al. (2003) · Investigational New Drugs · doi:10.1023/a:1022928612511 · Cited by 154
Fry, D. W. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00050-3 · Cited by 129
Therapeutic application of anti-growth factor receptor antibodies
Fan, Z., & Mendelsohn, J. M. (1998) · Current Opinion in Oncology · doi:10.1097/00001622-199801000-00011 · Cited by 119
Stumm, G., Eberwein, S., Rostock‐Wolf, S., Stein, H., Pomer, S., Schlegel, J., & Waldherr, R. (1996) · International Journal of Cancer · Cited by 112
WEBER, K. L., Doucet, M., Price, J. E., Baker, C. H., Kim, S. J., & Fidler, I. J. (2003) · PubMed · Cited by 105
Arteaga, C. L., & Baselga, J. M. (2003) · PubMed · Cited by 96
Strawn, L. M., & Shawver, L. K. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.4.553 · Cited by 79
Uncommon Presentations of Hodgkin's Disease: CASE 3. Hodgkin's Disease: Rectal Presentation
Simpson, L., Taylor, S. G., & Piotrowski, A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.144 · Cited by 58
Type I Receptor Tyrosine Kinases as Targets for Therapy in Breast Cancer
Baselga, J. M., & Mendelsohn, J. M. (1997) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1026355831693 · Cited by 31
Newlands, E. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.242 · Cited by 29
Cited by
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Cohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,554
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Segaert, S., & Van Cutsem, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi279 · Cited by 571
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Shih, T., & Lindley, C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521
Metadata
- Authors
- Rowinsky, E. K., Schwartz, G. H., Gollob, J. A., Thompson, J. A., Vogelzang, N. J., Figlin, R., Bukowski, R., Haas, N., Lockbaum, P., Li, Y.-P., Arends, R., Foon, K. A., Schwab, G., & Dutcher, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-08-01
- Volume
- 22
- Issue
- 15
- Pages
- 3003-3015
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2121306031
- Cited by
- 329
- References
- 31
- FWCI
- 35.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.